Table 2.
Baseline characteristics of the studies
| CORRECT | CONCUR | FRESCO | ||||
|---|---|---|---|---|---|---|
| Regorafenib N = 505 (%) | Placebo N = 255 (%) | Regorafenib N = 136 (%) | Placebo N = 68 (%) | Fruquintinib N = 278 (%) | Placebo N = 138 (%) | |
| Average age (year) | 61 | 61 | 57.5 | 55.5 | 55.0 | 57.0 |
| Sex | ||||||
| Man | 311 (62) | 153 (60) | 85 (63) | 33 (49) | 158 (56.8) | 97 (70.3) |
| Woman | 194 (38) | 102 (40) | 51 (38) | 35 (51) | 120 (43.2) | 41 (29.7) |
| ECOG PS | ||||||
| 0 | 265 (52) | 146 (57) | 35 (26) | 15 (22) | 77 (27.7) | 37 (26.8) |
| 1 | 240 (48) | 109 (43) | 101 (74) | 53 (78) | 201 (72.3) | 101 (73.2) |
| Race | ||||||
| White | 392 (78) | 201 (79) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Asian | 76 (15) | 35 (14) | 136 (100) | 68 (100) | 278 (100) | 138 (100) |
| Black | 6 (1) | 8 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Nonspecified | 31 (6) | 11 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Time from diagnosis of metastases | ||||||
| Median (months) | 31.0 | 29.9 | 20.3 | 19.9 | NA | NA |
| < 18 months | 91 (18) | 49 (19) | 53 (39) | 32 (47) | 163 (59) | 75 (54) |
| ≥ 18 months | 414 (82) | 206 (81) | 83 (61) | 36 (53) | 115 (41) | 63 (46) |
| Primary site of disease | ||||||
| Colon | 323 (64) | 172 (68) | 79 (58) | 48 (71) | 147 (53) | 70 (51) |
| Rectum | 151 (30) | 69 (27) | 53 (39) | 19 (28) | 125 (45) | 60 (44) |
| Colon and rectum | 30 (6) | 14 (5) | 4 (3) | 1 (1) | 6 (2.2) | 7 (5.1) |
| KRAS mutation | ||||||
| No | 205 (41) | 94 (37) | 50 (37) | 29 (43) | 157 (56.5) | 74 (53.6) |
| Yes | 273 (54) | 157 (62) | 46 (34) | 18 (26) | 121 (43.5) | 64 (46.4) |
| Unkown | 27 (5) | 4 (2) | 40 (29) | 21 (31) | NA | NA |
| Prior systemic chemotherapy (second-line or third-line) | ||||||
| 1–2 | 135 (27) | 63 (25) | 48 (35) | 24 (35) | NA | NA |
| 3 | 125 (25) | 72 (28) | 32 (24) | 17 (25) | NA | NA |
| ≥ 4 | 245 (49) | 120 (47) | 73 (54) | 27 (40) | NA | NA |
| Previous anti-VEGF treatment | ||||||
| Bevacizumab | 505 (100) | 255 (100) | 56 (41) | 25 (38) | 84 (30.2) | 41 (29.7) |
| Prior use of EGFR inhibitors | 219 (43) | 107 (42) | 48 (35) | 69 (32) | 40 (14.4) | 19 (13.8) |